Answers are grounded in this paper and cite their sources.
Discusses the rationale for using insulin sensitizers in women with PCOS due to the high prevalence of insulin resistance and obesity.
Polycystic Ovarian Syndrome (PCOS) is the leading endocrine disorder in women of childbearing age with a prevalence of more than 15% among this group.[1] These women are predisposed to obesity, have a predominance of the abdominal obesity phenotype associated with the hyperandrogenic state, insulin resistance (IR) and compensatory hyperinsulinemia.[2] [3] It is estimated that 80% of women with PCOS have IR, and this scenario worsens in the presence of obesity.[4] [5]
No takes yet. Share an insight, caveat, or question.
Marcos Felipe Silva de Sá (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: